1. A method of processing an image using an electronic device, the method comprising:
displaying at least part of a first image which is obtained through a first image sensor and at least part of a second image which is obtained through a second image sensor through a display unit which is functionally connected to the electronic device;
storing the at least part of the first image;
storing the at least part of the second image in response to a detecting of a signal; and
storing the at least part of the first image and the at least part of the second image to be simultaneously replayed as at least one image.
2. The method of claim 1, wherein the storing of the at least part of the second image comprises storing the at least part of the second image after a time period elapses from the detecting of the signal.
3. The method of claim 1, wherein the signal comprises a signal corresponding to a movement of the electronic device.
4. The method of claim 1, wherein the signal comprises at least one facial expression of a user which is related with the second image.
5. The method of claim 4, wherein the at least one facial expression of the user comprises at least one of a blink or a smile.
6. The method of claim 1, wherein the signal comprises at least one of a user gesture or an input of an input device.
7. A method of processing an image using an electronic device, the method comprising:
displaying at least part of a first image which is obtained through a first image sensor and at least part of a second image which is obtained through a second image sensor through a display unit which is functionally connected to the electronic device;
storing the at least part of the first image;
storing the at least part of the second image after a second time period elapses if a signal is detected;
storing the at least part of the second image if the signal is not detected within a first time period from the storing of the at least part of the first image; and
simultaneously replaying the at least part of the first image and the at least part of the second image as at least one image.
8. The method of claim 7, wherein the displaying of the at least part of the first image and the at least part of the second image comprises:
displaying the at least part of the first image as a first screen on the display unit; and
displaying the at least part of the second image as a second screen on the display unit.
9. The method of claim 7, wherein the displaying of the at least part of the first image and the at least part of the second image comprises:
providing a user interface for switching a location of the at least part of the first image displayed on the display unit with a location of the at least part of the second image.
10. The method of claim 7, wherein the displaying of the at least part of the first image and the at least part of the second image comprises:
obtaining the first image from a first side direction of the electronic device; and
obtaining the second image from a second side direction.
11. The method of claim 7, wherein the displaying of the at least part of the first image and the at least part of the second image comprises:
determining at least one of a location of the at least part of the first image displayed on the display unit or a location of the at least part of the second image, by using a location of a corresponding image sensor among the first image sensor and the second image sensor.
12. The method of claim 7, wherein the signal comprises at least one of a status of the electronic device or a status of a subject which is detected through at least one of the first image sensor or the second image sensor.
13. The method of claim 12, wherein the status of the electronic device comprises at least one of a rotation, swinging, or shaking of the electronic device.
14. The method of claim 12, wherein the status of the subject comprises at least one of a facial expression or an action.
15. The method of claim 14, wherein the facial expression of the subject comprises at least one of a blink or a smile.
16. The method of claim 7, wherein the storing of the at least part of the second image comprises:
operating a timer for measuring the second time period in response to the detecting of the signal.
17. An electronic device comprising:
a storage unit configured to store image information; and
a controller configured to process the image information,
wherein the controller is configured to display at least part of a first image, which is obtained through a first image sensor, and a part of a second image, which is obtained through a second image sensor, through a display unit which is functionally connected to the electronic device, to store the at least part of the first image, to store the at least part of the second image in response of a detecting of a signal, and to simultaneously replay the at least part of the first image and the at least part of the second image as one image.
18. The electronic device of claim 17, wherein the controller is configured to display the at least part of the first image as a first screen on the display unit and display the at least part of the second image as a second screen on the display.
19. The electronic device of claim 17, wherein the first image sensor is mounted on a first side of the electronic device, and the second image sensor is mounted on a second side of the electronic device.
20. The electronic device of claim 17, wherein the controller is configured to operate a first timer after storing the at least part of the first image when photography is requested, to operate a second timer if the signal is detected while the first timer is operating, to store the at least part of the second image when the second timer expires, and to store the at least part of the second image if the signal is not detected until the first timer expires.
21. The electronic device of claim 17, wherein the signal is a facial expression received via the second image sensor.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound represented by the structural formula (I):
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I),
wherein in Formula (I) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of \u2014CH2\u2014, \u2014CH(alkyl)- and \u2014C(alkyl)2-;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H. -G. \u2014(C1-C30 alkylene)-G, \u2014OR6, \u2014OC(O)R6, \u2014OC(O)OR9, \u2014OC(O)NR6R7 and -L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G, \u2014(C1-C30 alkylene)-G, \u2014OR6, \u2014(C1-C10 alkylene)-OR6, \u2014C(O)R6, \u2014(C1-C10 alkylene)-C(O)R6, \u2014C(O)OR6, \u2014(C1-C10 alkylene)-C(O)OR6, \u2014OC(O)R6, \u2014(C1-C10 alkylene)-OC(O)R6, \u2014OC(O)OR9, \u2014(C1-C10 alkylene)-OC(O)OR9, \u2014CH\u2550CH\u2014C(O)R6, \u2014CH\u2550CH\u2014C(O)OR6, \u2014C\u2261C\u2014C(O)OR6, \u2014C\u2261C\u2014C(O)R6, \u2014O\u2014(C1-C10 alkylene)-OR6, \u2014O\u2014(C10-C10 alkylene)-C(O)R6, \u2014O\u2014(C1-C10 alkylene)-C(O)OR6, \u2014CN, \u2014O\u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014O\u2014C(O)NR6NR7C(O)OR6, \u2014O\u2014(C1-C10 alkylene)-C(O)NR6NR7C(O)OR6, \u2014O\u2014(C1-C10 alkylene)-C(O)(aryl)-N3, \u2014OC(O)\u2014(C1-C10 alkylene)-C(O)OR6, \u2014C(O)NR6R7, \u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014OC(O)NR6R7, \u2014(C1-C10 alkylene)-OC(O)NR6R7, \u2014NO2, \u2014NR6R7, \u2014(C1-C10 alkylene)-NR6R7, \u2014O\u2014(C2-C10 alkylene-NR6R7, \u2014NR6C(O)R7, \u2014NR6C(O)OR9, \u2014NR6C(O)NR7R8, \u2014NR6S(O)0-2R9, \u2014N(S(O)0-2R9)2, \u2014CHNOR6, \u2014C(O)NR6R7, \u2014C(O)NR6NR6R7, \u2014S(O)0-2NR6R7, \u2014S(O)0-2R9, \u2014O\u2014C(O)\u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014OC(O)\u2014(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), \u2014P(O)(OR10)2, \u2014(C1-C10 alkylene)-OSi(alkyl)3, \u2014CF3, \u2014OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q4 iS 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G, \u2014(C1-C30 alkylene)-G, \u2014OR6, \u2014(C1-C10 alkylene)-OR6, \u2014C(O)R6, \u2014(C1-C10 alkylene)-C(O)R6, \u2014C(O)OR6, \u2014(C1-C10 alkylene)-C(O)OR6, \u2014OC(O)R6, \u2014(C1-C10 alkylene)-OC(O)R6, \u2014OC(O)OR9, \u2014(C1-C10 alkylene)-OC(O)OR9, \u2014CH\u2550CH\u2014C(O)R6, \u2014CH\u2550CH\u2014C(O)OR6, \u2014C\u2261C\u2014C(O)OR6, \u2014C\u2261C\u2014C(O)R6, \u2014O\u2014(C1-C10 alkylene)-OR6, \u2014O\u2014(C1-C10 alkylene)-C(O)R6, \u2014O\u2014(C1-C10 alkylene)-C(O)OR6, \u2014CN, \u2014O\u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014O\u2014C(O)NR6NR7 C(O)OR8, \u2014O\u2014(C1-C10 alkylene)-C(O)NR6NR7C(O)OR6, \u2014O\u2014(C1-C10 alkylene)-C(O)(aryl)-N3, \u2014OC(O)\u2014(C1-C10 alkylene)-C(O)OR6, \u2014C(O)NR6R7, \u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014OC(O)NR6R7, \u2014(C1-C10 alkylene)-OC(O)NR6R7, \u2014NO2, \u2014NR6R7, \u2014(C1-C10 alkylene)-NR6R7, \u2014O\u2014(C2-C10 alkylene)-NR6R7, \u2014NR6C(O)R7 , \u2014NR6C(O)OR9, \u2014NR6C(O)NR7R8, \u2014NR6S(O)0-2R9, N(S(O)0-2R9)2, \u2014CHNOR6, \u2014C(O)NR6R7, \u2014C(O)NR6NR6R7, \u2014S(O)0-2R9, \u2014O\u2014C(O)\u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014OC(O)\u2014(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), \u2014P(O)(OR10)2, \u2014(C1-C10 alkylene)-OSi(alkyl)3, \u2014CF3, \u2014OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G, \u2014(C1-C10 alkylene)-G, \u2014OR6, \u2014(C1-C10 alkylene)-OR6, \u2014C(O)R6, \u2014(C1-C10 alkylene)-C(O)R6, \u2014C(O)OR6, \u2014(C1-C10 alkylene)-C(O)OR6, \u2014OC(O)R6, (C1-C10 alkylene)-OC(O)R6, \u2014OC(O)OR9, \u2014(C1-C10 alkylene)-OC(O)OR9, \u2014CH\u2550CH\u2014C(O)R6, \u2014CH\u2550CH\u2014C(O)OR6, \u2014C\u2261C\u2014C(O)OR6, \u2014C\u2261C\u2014C(O)R6, \u2014O\u2014(C1-C10 alkylene)-OR6, \u2014O-(C1-C10 alkylene)-C(O)R6, \u2014O\u2014(C1-C10 alkylene)-C(O)OR6, \u2014CN, \u2014O\u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014O\u2014C(O)NR6NR7 C(O)OR6, \u2014O\u2014(C1-C10 alkylene)-C(O)NR6NR7C(O)OR6, \u2014O\u2014(C1-C10 alkylene)-C(O)(aryl)-N3, \u2014OC(O)\u2014(C1-C10 alkylene)-C(O)OR6, \u2014C(O)NR6R7, \u2014(C1-C10 alkylene)-C(O)NR6R7, \u2014OC(O)NR6R7, \u2014(C1-C10 alkylene)-OC(O)NR6R7, \u2014NO2, \u2014NR6R7, \u2014(C1-C10 alkylene)-NR6R7, \u2014O\u2014(C2-C10 alkylene)-NR6R7, \u2014NR6C(O)R7, \u2014NR6C(O)OR9, \u2014NR6C(O)NR7R8, \u2014NR6S(O)0-2R9, \u2014N(S(O)0-2R9)2, \u2014CHNOR6, \u2014C(O)NR6R7, \u2014C(O)NR6NR6R7, \u2014S(O)0-2NR6R7, \u2014S(O)0-2R9, \u2014O\u2014C(O)\u2014(C1-C10 alkylene)-C(O)N R6R7, \u2014OC(O)\u2014(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), \u2014P(O)(OR10)2, \u2014(C1-C10 alkylene)-OSi(alkyl)3, \u2014CF3, \u2014OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
wherein optionally one or more carbon atoms of the \u2014(C1-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by \u2014O\u2014, \u2014C(O)\u2014, \u2014CH\u2550CH\u2014, \u2014C\u2261C\u2014, \u2014N(alkyl)-, \u2014N(alkylaryl)- or \u2014NH\u2014;
G is an oligopeptide residue comprising 2 to 9 amino acids, wherein optionally the oligopeptide residue of G is substituted with -L-M;
L is selected from the group consisting of
wherein Me is methyl;
M is selected from the group of moieties consisting of
pharmaceutically acceptable salts of the moieties (M1) to (M9) and free acids of the moieties (M1) to (M9);
R2 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and
each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
x1 is 1 to 10;
x2 is 1 to 10;
x3 is 1 to 10;
x4 is 1 to 10;
x5 is 1 to 10;
x6 is 1 to 10; and
x7 is 1 to 10;
x8 is 1 to 10;
x9 is 1 to 10;
x10 is 1 to 10; and
x11 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is the oligopeptide residue of G substituted with -L-M, and
wherein each of the above alkyl, alkenyl, alkynyl, alkylene, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, or heterocyclylcarbonylalkoxy groups, when present, is independently substituted or unsubstituted.
2. The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is \u2014CH2\u2014.
3. The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is \u2014CH2-, Q1 is \u2014OR6, wherein R6 is hydrogen and Q5 is fluorine.
4. The compound according to claim 1, wherein R2 and R3 are each hydrogen.
5. The compound according to claim 1, wherein Q1 and Q2 are each independently selected from the group consisting of \u2014OR6, \u2014O(CO)R6, \u2014O(CO)OR9 and \u2014O(CO)NR6R7.
6. The compound according to claim 1, wherein Q4 is halo or \u2014OR6.
7. The compound according to claim 1, wherein Q1 is \u2014OR6 wherein R6 is H.
8. The compound according to claim 1, wherein Q1, Q2, Q3, Q4 or Q5 is -L-M.
9. The compound according to claim 1, wherein Q1, Q2, Q3, Q4 or Q5 is -G or \u2014(C1-C30 alkylene)-G.
10. The compound according to claim 1, wherein optionally one or more carbon atoms of the \u2014(C1-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by \u2014O\u2014.
11. The compound according to claim 1, wherein L is
12. The compound according to claim 1, wherein L is
13. The compound according to claim 1, wherein M is
or pharmaceutically acceptable salts thereof.
14. The compound according to claim 1, wherein M is
or pharmaceutically acceptable salts thereof.
15. The compound according to claim 1, wherein M is
or pharmaceutically acceptable salts thereof.
16. The compound according to claim 1, wherein M is
or pharmaceutically acceptable salts thereof.
17. The compound according to claim 1, wherein M is
or pharmaceutically acceptable salts thereof.
18. A pharmaceutical composition for the treatment of atherosclerosis, hypercholesterolemia, or sitosterolemia, or for lowering a concentration of cholesterol, phytosterol or 5\u03b1-stanol in plasma of a subject comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
20. A method of treating atherosclerosis, hypercholesterolemia, or sitosterolemia, or for lowering a concentration of cholesterol, phytosterol or 5\u03b1-stanol in plasma of a subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 1.
21. A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 1.